The Role of IL-17 Cytokines in Psoriasis

被引：51
作者：
Mosca, Megan [1 ]
Hong, Julie [1 ]
Hadeler, Edward [1 ]
Hakimi, Marwa [1 ]
Liao, Wilson [1 ]
Bhutani, Tina [1 ]
机构：
[1] Univ Calif San Francisco, Psoriasis & Skin Treatment Ctr, Dept Dermatol, 515 Spruce St, San Francisco, CA 94118 USA
来源：
IMMUNOTARGETS AND THERAPY | 2021年 / 10卷
关键词：
IL-17; plaque psoriasis; pathogenesis; biologics; immune pathway; SEVERE PLAQUE PSORIASIS; DOUBLE-BLIND; METABOLIC SYNDROME; CONTROLLED-TRIAL; MODERATE; USTEKINUMAB; SECUKINUMAB; EFFICACY; SAFETY; CELLS;
D O I：
10.2147/ITT.S240891
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Psoriasis is a chronic inflammatory skin condition associated with immune dysregulation. The immunologic cascade mediated by the interleukin (IL)-17 pathway plays a critically important role in the pathogenesis of psoriasis. The IL-17 effectors (IL17A, IL-17C, IL-17E, and IL17F) act on keratinocytes, endothelial cells, and immune cells to stimulate epidermal hyperplasia and the pro-inflammatory feed-forward cycle seen within plaque psoriasis. The IL-17 pathway is also hypothesized to modulate the inflammatory responses linking comorbid systemic diseases with psoriasis. Furthermore, the robust clinical response seen with current and emerging therapies targeting IL-17 emphasizes the importance of the IL-17 cytokines in the pathogenesis of psoriasis.
引用
收藏
页码：409 / 418
页数：10
相关论文
共 78 条
  • [1] Interleukin 23 Levels Are Increased in Carotid Atherosclerosis Possible Role for the Interleukin 23/Interleukin 17 Axis
    Abbas, Azhar
    Gregersen, Ida
    Holm, Sverre
    Daissormont, Isabelle
    Bjerkeli, Vigdis
    Krohg-Sorensen, Kirsten
    Skagen, Karolina R.
    Dahl, Tuva B.
    Russell, David
    Almas, Trine
    Bundgaard, Dorte
    Alteheld, Lars Holger
    Rashidi, Azita
    Dahl, Christen P.
    Michelsen, Annika E.
    Biessen, Erik A.
    Aukrust, Pal
    Halvorsen, Bente
    Skjelland, Mona
    [J]. STROKE, 2015, 46 (03) : 793 - +
  • [2] Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17
    Aggarwal, S
    Ghilardi, N
    Xie, MH
    de Sauvage, FJ
    Gurney, AL
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (03) : 1910 - 1914
  • [3] Expansion of CD4 T Lymphocytes Expressing Interleukin 17 and Tumor Necrosis Factor in Patients with Major Depressive Disorder
    Alvarez-Mon, Miguel Angel
    Gomez-Lahoz, Ana Maria
    Orozco, Arancha
    Lahera, Guillermo
    Diaz, David
    Ortega, Miguel A.
    Albillos, Agustin
    Quintero, Javier
    Auba, Enrique
    Monserrat, Jorge
    Alvarez-Mon, Melchor
    [J]. JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (03):
  • [4] Alwan W, 2015, CLIN EXP RHEUMATOL, V33, pS2
  • [5] [Anonymous], 2021, HIGHLIGHTS PRESCRIBI
  • [6] [Anonymous], 2020, Highlights of Prescribing Information Abraxane
  • [7] Pathophysiology, Clinical Presentation, and Treatment of Psoriasis A Review
    Armstrong, April W.
    Read, Charlotte
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (19): : 1945 - 1960
  • [8] Psoriasis and metabolic syndrome: A systematic review and meta-analysis of observational studies
    Armstrong, April W.
    Harskamp, Caitlin T.
    Armstrong, Ehrin J.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 68 (04) : 654 - 662
  • [9] Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY)
    Bagel, J.
    Blauvelt, A.
    Nia, J.
    Hashim, P.
    Patekar, M.
    de Vera, A.
    Ahmad, K.
    Paguet, B.
    Xia, S.
    Muscianisi, E.
    Lebwohl, M.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (01) : 135 - 142
  • [10] Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
    Bagel, Jerry
    Nia, John
    Hashim, Peter W.
    Patekar, Manmath
    de Vera, Ana
    Hugot, Sophie
    Sheng, Kuan
    Xia, Summer
    Gilloteau, Isabelle
    Muscianisi, Elisa
    Blauvelt, Andrew
    Lebwohl, Mark
    [J]. DERMATOLOGY AND THERAPY, 2018, 8 (04) : 571 - 579
12345678